Comparison of an Attention-Based Multiple Instance Learning (MIL) With a Visual Transformer Model: Two Weakly Supervised Deep Learning (DL) Algorithms for the Detection of Histopathologic Lesions in the Rat Liver to Distinguish Normal From Abnormal.

Journal: Toxicologic pathology
Published Date:

Abstract

The histopathologic evaluation of regulatory toxicity studies using artificial intelligence (AI) has the potential to increase study efficiency. For example, AI could initially identify and exclude all organs without histopathologic lesions, allowing pathologists to focus solely on evaluating organs with identified lesions. In this study, whole slide images (WSIs) of liver sections from 58 different rat toxicity studies were collected, along with their corresponding histopathologic lesion diagnoses. Each WSI was labeled as either "lesion" or "no lesion" based on the presence or absence of reported histopathologic lesions. Multiple instance learning (MIL) approaches, including a transformer variant, were tested to predict lesions within a weakly supervised framework. Both methods achieved acceptable to excellent area under the receiver operating characteristic curve (AUROC) scores. Heatmap overlays were employed to visually assess the MIL model's effectiveness in detecting lesions, confirming the accuracy of targeted areas on the WSIs. In addition, using transfer learning principles, the MIL model initially developed for liver WSIs was adapted to kidney WSIs, demonstrating the model's versatility. This study showcases the application of weakly supervised learning for lesion detection in rat WSIs from toxicity studies, with the potential to significantly enhance the efficiency of the histopathologic evaluation process.

Authors

  • Juergen Funk
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Gregoire Clement
    Visium, Zurich, Switzerland.
  • Matteo Togninalli
    Visium, Lausanne 1015, Switzerland.
  • Yaniv Cohen
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Tom Albrecht
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Ruth Sullivan
    Genentech Inc., South San Francisco, California, USA.
  • Josep Arus Pous
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Marco Tecilla
    Roche Pharmaceutical Research and Early Development (pRED), Basel, Switzerland.
  • Fernando Romero-Palomo
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Amadeusz Abramowski
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Angelo D'Annunzio
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Yun Yvonna Li
    F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Trung Nguyen
    Genentech Inc., South San Francisco, California, USA.
  • Fangyao Hu
    Department of Safety Assessment, Genentech, South San Francisco, CA, USA.
  • Vanessa Schumacher
    Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, 1529F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Keywords

No keywords available for this article.